ZNTL
NASDAQZentalis Pharmaceuticals Inc.
Website
News25/Ratings12
News · 26 weeks36+50%
2025-10-262026-04-19
Mix1690d
- Other7(44%)
- Insider4(25%)
- SEC Filings4(25%)
- Analyst1(6%)
Latest news
25 items- PRZentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian CancerSAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that the American Society of Clinical Oncology (ASCO) has accepted an abstract for presentation at the 2026 ASCO Annual Meeting, which will be held June 1-5, 2026, in Chicago, IL. "We are pleased that data from Part 1 of the MUIR trial focusing on azenosertib in combination with paclitaxel in platinum-resistant ovarian cancer (PROC) have been accepted for presentation at ASCO," said Julie Eastland, C
- PRZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancer Real-world data demonstrate Cyclin E1-positive ovarian cancer patients have significantly worse outcomes, independent of CCNE1 gene amplification status, reinforcing the potential for azenosertib to address the unmet need for these patients SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announce
- SECZentalis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
- SECZentalis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
- PRZentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian CancerPlanned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groupsAzenosertib therapeutic profile supports Phase 2 DENALI and Phase 3 ASPENOVA advancement as well as initiation of pre-commercial activitiesDENALI Part 2 topline readout expected by year end 2026 SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced the selection of 400mg on
- PRZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on April 1, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 36,000 shares of the Company's common stock to two newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such in
- SECSEC Form 10-K filed by Zentalis Pharmaceuticals Inc.10-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
- SECZentalis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
- PRZentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer Demonstration of Cyclin E1 protein overexpression as an indicator for poor prognosis in ovarian cancer patients with real world data SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 202
- ANALYSTWells Fargo resumed coverage on Zentalis Pharma with a new price targetWells Fargo resumed coverage of Zentalis Pharma with a rating of Equal Weight and set a new price target of $5.00
- PRZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesSAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference, Virtual. Fireside discussion, February 25, 2026, 12:40 p.m. ET.TD Cowen 45th Annual Health Care Conference, Boston, MA. Fireside discussion, March 3, 2026, 10:30 a.m. ET.Leerink Partners Global Healthcare Conference, Miami, FL. Fireside discu
- INSIDERChief Medical Officer Bruns Ingmar sold $7,998 worth of shares (3,297 units at $2.43), decreasing direct ownership by 9% to 33,332 units (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERPAO and PFO Vultaggio Vincent sold $97,557 worth of shares (40,224 units at $2.43), decreasing direct ownership by 22% to 146,506 units (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERCEO & President Eastland Julia Marie sold $21,239 worth of shares (8,755 units at $2.43), decreasing direct ownership by 10% to 79,133 units (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERPAO and PFO Vultaggio Vincent sold $7,875 worth of shares (3,096 units at $2.54), decreasing direct ownership by 2% to 186,730 units (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- PRZentalis Pharmaceuticals to Participate in Upcoming Investor ConferenceSAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in a fireside discussion during Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11th in New York, NY at 3:30 p.m. ET. Access to a live webcast of the event, as well as an archived recording, will be available for at least 30 days after each live event concludes under the "Events & Presentations" tab on the Investors & Media section of
- PRFast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 12, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as genomics in cancer care expands toward a projected $69.16 billion by 2032[1]. This massive growth is driven by the systematic integration of genotype-directed treatment pathways into standard medical practice. The precision medicine market is now on a trajectory to expand from $138.67 billion in 2026 to over $537.17 billion by 2035[2]. This strategic pivot toward registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), CG Oncology (NASDAQ:CGON), Ze
- INSIDERSEC Form 4 filed by PAO and PFO Vultaggio Vincent4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Bucher James B4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Bruns Ingmar4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERSEC Form 4 filed by CEO & President Eastland Julia Marie4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- SECZentalis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
- INSIDERLarge owner Walters Group bought $7,751,968 worth of shares (6,459,973 units at $1.20) (SEC Form 4)4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- INSIDERNew insider Walters Group claimed ownership of 7,050,000 shares (SEC Form 3)3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
- PRZentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalInitiation of the ASPENOVA Phase 3, randomized, confirmatory trial planned in 1H 2026 SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today provided a corporate update and highlighted key milestones and expected momentum in the azenosertib development program for 2026. "2026 represents